1 May 2023 • Shingrix was approved by the US Food and Drug Administration (FDA) for the prevention of shingles in adults 50 years of age or older in 2017. The launch of Shingrix was announced in India last week. The vaccine is aimed at the prevention of shingles (herpes zoster) and post-herpetic neuralgia.

Shingrix is the world’s first non-live, recombinant subunit vaccine to be given intramuscularly in two doses, the company said in a statement. The vaccine, Shingrix, as per the company, can provide at least 10 years of protection against Shingles. The vaccine has proven efficacy of more than 90 per cent against shingles, the statement added.

A seroprevalence study in Indian subjects showed that by the age of 40, more than 90 per cent were vulnerable to shingles.

About Shingrix Shingrix (Zoster Vaccine Recombinant, Adjuvanted) is a non-live, recombinant subunit vaccine to help prevent shingles. Shingrix combines an antigen, glycoprotein E, and an adjuvant system, AS01B, intended to generate a strong and long-lasting immune response that can help overcome the decline in immunity as people age. The European Commission gave Shingrix approval for the prevention of shingles in adults 50 years of age or older in 2018.

Source: ET Health | Read press release